

COMPANY OVERVIEW

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focussing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson's disease (PD), Alzheimer's disease (AD) and other related neurodegenerative diseases.

RECENT NEWS

Cantabio Pharmaceuticals to Present Latest Positive In Vivo Results From its DJ-1 Targeting Small Molecule Drug Development Program for Parkinson's Disease at the Milner Therapeutics Symposium at the University of Cambridge, UK

Oct 1 2018, 9:05 AM EDT

STOCK OVERVIEW

Symbol	CTBO
Exchange	OTCPink
Market Cap	395.57k
Last Price	\$0.007
52-Week Range	\$0.007 - \$0.13

12/13/2018 11:23 AM EST

INVESTOR RELATIONS

Russo Partners LLC
12 West 27th Street
4th Floor
New York, NY 10001
T: (844) 200-CTBO
ir@cantabio.com

MANAGEMENT TEAM

Gergely Tóth, Ph.D., M.B.A.
Founder, Chief Executive Officer

Simon Peace, M.Sc., M.B.A., A.C.M.A.
Chief Financial Officer

Thomas Sawyer, Ph.D., M.B.A.
Chief Operations Officer

CANTABIO PHARMACEUTICALS INC.

1250 Oakmead Pkwy
Sunnyvale, CA 94085
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.